Nicotine
Limited Stage Small Cell Lung Cancer
Wake Forest University Health SciencesSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Limited Stage Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benmelstobart Yayi He | Phase 4 | A |
Orm-6151 Bristol-Myers Squibb | Phase 2 | B |
Ociperlimab BeiGene | Phase 2 | B |
Tirapazamine National Cancer Institute (NCI) | Phase 2 | B |
Pamiparib Fudan University | Phase 2 | CCC |
Anlotinib Hydrochloride Capsules Jinming Yu | Phase 1 | CC |
Same molecule, other indications
Nicotine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →